Celecoxib's effect on inflammatory response in patients receiving thoracic and abdominal surgery (Phase II study)

Peter MacCallum Cancer Centre0 个研究点目标入组 30 人开始时间: 2015年1月20日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Patients receiving thoracic surgery or laparotomy (expected duration greater than two hours) at Peter MacCallum Cancer Centre. Surgical subtypes include patients receiving thoracotomy or thoracoscopic surgery where surgery is performed in the intra-pleural space, and patients receiving a laparotomy (expected >2 hours);
•- Age >18 years old;
•- World Health Organization ECOG performance status 0 or 1;
•- At least five days since use of prior non-steroidal anti-inflammatory agents including Aspirin, Celecoxib, Ibuprofen, Naproxen, Meloxicam, Diclofenac;
•- Written, informed consent.

•contraindications to celecoxib,
•robotic assisted thoracoscopic surgery,
•acute inflammatory condition (sepsis, infection),
•pregnancy or lactation,
•concurrent use of oral corticosteroid treatment or NSAID/aspirin (within a week prior to study entry),
•presence of neuroendocrine tumour,
•hepatic impairment (aspartate transaminase >240 u/L, alanine transaminase >110 u/L) renal impairment (creatinine >150 umol/L).

发起方

Peter MacCallum Cancer Centre